CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-20 | AHMED NADIM President and CEO | Sale | −16,381 | $13.62 | $223K | 404,318 |
| 2026-02-18 | SUMER JACQUELYN L Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +230,000 | 230,000 | ||
| 2026-02-18 | Jones Jeffrey Alan Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2026-02-18 | AHMED NADIM President and CEO | Grant or award · Stock Option (Right to Buy) | +828,000 | 828,000 | ||
| 2026-02-18 | Savill Corrine Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2026-02-18 | Fenton Mary Kay Chief Financial Officer | Grant or award | +68,750 | 130,778 | ||
| 2026-02-18 | Fenton Mary Kay Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +137,500 | 137,500 | ||
| 2026-02-18 | Michaelson Jennifer Chief Scientific Officer | Grant or award | +57,500 | 185,719 | ||
| 2026-02-18 | Michaelson Jennifer Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2026-02-12 | Michaelson Jennifer Chief Scientific Officer | Sale | −416 | $12.03 | $5K | 128,219 |
| 2026-01-22 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −4,000 | $12.30 | $49K | 128,635 |
| 2025-12-31 | Fenton Mary Kay Chief Financial Officer | Grant or award | +27 | $6.49 | $175 | 62,028 |
| 2025-12-23 | AHMED NADIM President and CEO | Sale | −9,922 | $10.01 | $99K | 420,699 |
| 2025-12-19 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −1,345 | $10.01 | $13K | 132,635 |
| 2025-12-18 | SUMER JACQUELYN L Chief Legal Officer | Sale | −3,480 | $9.67 | $34K | 135,432 |
| 2025-12-18 | Jones Jeffrey Alan Chief Medical Officer | Sale | −4,632 | $9.67 | $45K | 169,532 |
| 2025-12-18 | Michaelson Jennifer Chief Scientific Officer | Sale | −2,898 | $9.67 | $28K | 133,980 |
| 2025-12-15 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −995 | $11.90 | $12K | 136,878 |
| 2025-12-12 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −2,148 | $12.38 | $27K | 137,873 |
| 2025-11-24 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −4,000 | $12.30 | $49K | 138,004 |
Page 3 of 23 · 446 trades